Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,650.80
(
1.28%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
103.69
(
-1.96%
)
Bitcoin
79,304.18
(
-1.47%
)
News Focus
News Focus

Replies to post #15900 on RespireRx Pharmaceuticals Inc (fka RSPI)

Replies to #15900 on RespireRx Pharmaceuticals Inc (fka RSPI)
icon url

rusbrn

03/08/08 11:42 AM

#15902 RE: gfp927z #15900

Why would a compound other than 717 have to be included in a RD deal? The patent life of the compound is irrelevant in this case as the indication is patented and the artifact would not be in play as usage would not be chronic.
Russ.